Replies to post #56268 on Anavex Life Sciences Corp (AVXL)

[MinnieM]

Interesting point.





In Reply to 'jimmy667
12 week data is opportunity for bashing. BP might like the fact that if A2-73 if approved would likely be RX'd for life. So it might be that the 2 year extension is much more important for positive share price than the 12 week data and almost impossible to twist and bash. It is just as likely to tank on the announcement of 12 week data as it is on not announcing the 12 week data maybe more so. No one expects a miracle but if not outstanding could lead to bashing. But the two year extension merely drills home the realization that if approved will likely be RX'd for life making it a potential blockbuster commercial success. Jmho

[TomP1]

You're making an excellent point.

And given the fact that yesterday there were tweets again by JF and AF (after months of silence), only tells me that further manipulation will happen. I do expect negative articles again, full of twists and factual untruths, but that is the game.

Luckily this time the pps has not been inflated like in November.

Furthermore, there has been a big increase of postings on this board in the last couple of days and arrival of many new posters. This too is a sign on the wall.

[Amatuer17]

Good point - in fact this is one speciality of CNS -Heart -HIV medicies - they need to be taken over very long time. (Lipitor is one great example)

BP who are searching for new continuous source of revenue will find A2-73 very attractive even if it shows partial response that is better than Aricept.

Add to that other CNS indications and they will get a goldmine

[Diamondhands45]

I think that is anavex works without donezepil, that was the biggest thing in that PR